Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results

In 2 double-blind phase 3 trials, 1733 antiretroviral-naive adults were randomized to tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir/cobicistat/emtricitabine (E/C/F). At 144 weeks, TAF was superior to TDF in virologic efficacy, with 84.2% vs 8...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of acquired immune deficiency syndromes (1999) 2017-06, Vol.75 (2), p.211-218
Hauptverfasser:	Arribas, José R, Thompson, Melanie, Sax, Paul E, Haas, Bernhard, McDonald, Cheryl, Wohl, David A, DeJesus, Edwin, Clarke, Amanda E, Guo, Susan, Wang, Hui, Callebaut, Christian, Plummer, Andrew, Cheng, Andrew, Das, Moupali, McCallister, Scott
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - analogs & derivatives Adenine - therapeutic use Alanine Anti-HIV Agents - therapeutic use Bone Density - drug effects CD4 Lymphocyte Count Cobicistat - therapeutic use Double-Blind Method Emtricitabine - therapeutic use HIV Infections - drug therapy HIV Infections - immunology Humans Middle Aged Quinolones - therapeutic use Tenofovir - therapeutic use Treatment Outcome United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In 2 double-blind phase 3 trials, 1733 antiretroviral-naive adults were randomized to tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir/cobicistat/emtricitabine (E/C/F). At 144 weeks, TAF was superior to TDF in virologic efficacy, with 84.2% vs 80.0% having HIV-1 RNA
ISSN:	1525-4135 1944-7884
DOI:	10.1097/QAI.0000000000001350